Do you know how to get the J-START quality assurance guideline?

Excerpt

The Japan Strategic Anti-cancer Randomized Trial (J-START), which is the world’s first large-scale randomized controlled trial of supplemental screening breast ultrasonography in asymptomatic women aged 40–49 years, which has being conducted in Japan, assessed the efficacy of mammography with adjunctive ultrasonography in improving sensitivity and detection rates of early breast cancers in The Lancet [1]. Preliminary results from the J-START showed that the sensitivity was significantly higher in the intervention group than in the control group (91.1 vs. 77.0%; p = 0.0004), whereas the specificity was significantly lower (87.7 vs. 91.4%; p < 0.0001). More cancers were detected in the intervention group than in the control group [184 (0.50%) vs. 117 (0.32%); p = 0.0003] and were more frequently stages 0 and 1 [144 (71.3%) vs. 79 (52.0%); p = 0.0194]. Furthermore, there was a significant reduction in interval cancers (0.05 vs. 0.10%; p = 0.034). Although the mortality rates are the most important parameters to evaluate the efficacy of supplemental screening breast ultrasonography, preliminary results from the J-START are essential in informing personalized supplemental screening modality choices for women with dense breasts. …